MEDNAX
Market Cap
US$1.9b
Last Updated
2019/10/23 00:11 UTC
Data Sources
Company Financials +
Executive Summary
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico.
Snowflake
Fundamentals
Very undervalued with moderate growth potential.
Similar Companies
Share Price & News
How has MEDNAX's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.3%
MD
3.9%
US Healthcare
0.07%
US Market
1 Year Return
-42.8%
MD
-6.7%
US Healthcare
8.9%
US Market
Return vs Industry: MD underperformed the US Healthcare industry which returned -6.7% over the past year.
Return vs Market: MD underperformed the US Market which returned 8.9% over the past year.
Shareholder returns
| MD | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.3% | 3.9% | 0.07% |
| 30 Day | 1.0% | 3.5% | -0.3% |
| 90 Day | 0.6% | -0.05% | -1.6% |
| 1 Year | -42.8%-42.8% | -5.1%-6.7% | 11.3%8.9% |
| 3 Year | -64.0%-64.0% | 37.0%30.6% | 46.3%36.8% |
| 5 Year | -58.7%-58.7% | 61.3%50.4% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is MEDNAX's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Here's Why MEDNAX (NYSE:MD) Has A Meaningful Debt Burden1 month ago | Simply Wall St
How Do MEDNAX, Inc.’s (NYSE:MD) Returns On Capital Compare To Peers?1 month ago | Simply Wall St
Those Who Purchased MEDNAX (NYSE:MD) Shares Three Years Ago Have A 68% Loss To Show For ItValuation
Is MEDNAX undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MD ($23.42) is trading below our estimate of fair value ($58)
Significantly Below Fair Value: MD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MD is good value based on its PE Ratio (9.7x) compared to the Healthcare industry average (21x).
PE vs Market: MD is good value based on its PE Ratio (9.7x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: MD is good value based on its PEG Ratio (0.2x)
Price to Book Ratio
PB vs Industry: MD is good value based on its PB Ratio (0.7x) compared to the US Healthcare industry average (2.5x).
Next Steps
Future Growth
How is MEDNAX forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
47.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MD's forecast earnings growth (47.1% per year) is above the savings rate (2.7%).
Earnings vs Market: MD's earnings (47.1% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MD's revenue (1.6% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: MD's revenue (1.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MD's Return on Equity is forecast to be low in 3 years time (9.8%).
Next Steps
Past Performance
How has MEDNAX performed over the past 5 years?
-3.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: MD's earnings have declined by -3.4% per year over the past 5 years.
Accelerating Growth: MD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MD had negative earnings growth (-37.3%) over the past year, making it difficult to compare to the Healthcare industry average (5.6%).
Return on Equity
High ROE: MD's Return on Equity (7.7%) is considered low.
Return on Assets
ROA vs Industry: MD has a higher Return on Assets than the Healthcare industry average last year.
Return on Capital Employed
ROCE Improving: MD's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is MEDNAX's financial position?
Financial Position Analysis
Short Term Liabilities: MD's short term assets ($985.5M) exceeds its short term liabilities ($441.0M)
Long Term Liabilities: MD's short term assets (985.5M) do not cover its long term liabilities (2.5B)
Debt to Equity History and Analysis
Debt Level: MD's debt to equity ratio (76.3%) is considered high
Reducing Debt: MD's debt to equity ratio has increased from 7.5% to 76.3% over the past 5 years.
Debt Coverage: MD's debt is not well covered by operating cash flow (15.9%).
Interest Coverage: MD's interest payments on its debt are well covered by EBIT (4x coverage).
Balance Sheet
Inventory Level: MD has a low level of unsold assets or inventory.
Debt Coverage by Assets: MD's debt is not covered by short term assets (assets are 0.5x debt).
Next Steps
Dividend
What is MEDNAX's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate MD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if MD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of MEDNAX's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Roger Medel (72yo)
16.6yrs
Tenure
US$9,938,017
Compensation
Dr. Roger J. Medel, M.D., Co-Founded at MEDNAX, Inc. (also known as Pediatrix Medical Group Inc.) in 1979. Dr. Medel served as the MEDNAX, Inc.’s President until May 2000 and as Chief Executive Officer unt ...
CEO Compensation Analysis
Compensation vs. Market: Roger's total compensation ($USD9.94M) is above average for companies of similar size in the US market ($USD4.07M).
Compensation vs Earnings: Roger's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Management Age and Tenure
2.8yrs
Average Tenure
52yo
Average Age
Experienced Management: MD's management team is considered experienced (2.8 years average tenure).
Board Age and Tenure
15.4yrs
Average Tenure
66yo
Average Age
Experienced Board: MD's board of directors are seasoned and experienced ( 15.4 years average tenure).
Insider Trading
Insider Buying: MD insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 122,409 |
| Max Price | US$21.35 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 377,591 |
| Max Price | US$21.68 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,300 |
| Max Price | US$30.40 |
Ownership Breakdown
Management Team
Steve Farber (49yo)
Executive VP & CFO
- Tenure: 0.9yrs
- Compensation: US$5.75m
Roger Medel (72yo)
Co-Founder
- Tenure: 16.6yrs
- Compensation: US$9.94m
Claire Fair
Chief Human Resources Officer
- Tenure: 0.8yrs
John Pepia (56yo)
Senior VP & Chief Accounting Officer
- Tenure: 3.4yrs
David Clark (52yo)
Chief Operating Officer
- Tenure: 0.7yrs
- Compensation: US$3.95m
Charles Lynch
Vice President of Strategy & Investor Relations
- Tenure: 0yrs
James Swift
Chief Development Officer
- Tenure: 5.8yrs
Tony Ambegaoker
Corporate Chief Information Officer
- Tenure: 2.8yrs
Dominic Andreano (50yo)
Senior VP
- Tenure: 7.4yrs
- Compensation: US$2.01m
Mary Ann Moore
Chief Compliance Officer
- Tenure: 0.8yrs
Board Members
Paul Gabos (53yo)
Independent Director
- Tenure: 16.9yrs
- Compensation: US$220.01k
Roger Medel (72yo)
Co-Founder
- Tenure: 16.6yrs
- Compensation: US$9.94m
Cesar Alvarez (71yo)
Independent Chairman of the Board
- Tenure: 15.4yrs
- Compensation: US$250.01k
Enrique Sosa (79yo)
Independent Director
- Tenure: 15.4yrs
- Compensation: US$200.01k
Mike Fernandez (66yo)
Independent Director
- Tenure: 24yrs
- Compensation: US$200.01k
Waldemar Carlo (66yo)
Independent Director
- Tenure: 20.3yrs
- Compensation: US$210.01k
Manuel Kadre (53yo)
Lead Independent Director
- Tenure: 5.6yrs
- Compensation: US$235.01k
Pascal Goldschmidt (64yo)
Independent Director
- Tenure: 13.6yrs
- Compensation: US$210.01k
Karey Barker (51yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: US$200.01k
Carlos Migoya (68yo)
Director
- Tenure: 0.4yrs
Company Information
MEDNAX, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: MEDNAX, Inc.
- Ticker: MD
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.942b
- Shares outstanding: 82.90m
- Website: https://www.mednax.com
Number of Employees
Location
- MEDNAX, Inc.
- 1301 Concord Terrace
- Sunrise
- Florida
- 33323
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MD | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Sep 1995 |
| PDC | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 1995 |
| MD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Sep 1995 |
Biography
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the Uni ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 00:11 |
| End of Day Share Price | 2019/10/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.